Page 1886 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 5

diagnosis of allergy: technical issues and critical factors. Allergy. 154. De Soto H, Turk P. Cimetidine in anaphylactic shock refractory
September 2009;64(9):1319-1326. to standard therapy. Anesth Analg. August 1989;69(2):264-265.
138. Steckelbroeck S, Ballmer-Weber BK, Vieths S. Potential, pit- 155. Yarbrough JA, Moffitt JE, Brown DA, Stafford CT. Cimetidine in
falls, and prospects of food allergy diagnostics with recombi- the treatment of refractory anaphylaxis. Ann Allergy. September
nant allergens or synthetic sequential epitopes. J Allergy Clin 1989;63(3):235-238.
Immunol. June 2008;121(6):1323-1330. 156. Mayumi H, Kimura S, Asano M, Shimokawa T, Au-Yong TF,
139. Lin J, Bardina L, Shreffler WG, et al. Development of a Yayama T. Intravenous cimetidine as an effective treatment
novel peptide microarray for large-scale epitope mapping of for systemic anaphylaxis and acute allergic skin reactions. Ann
food allergens. J Allergy Clin Immunol. August 2009;124(2): Allergy. June 1987;58(6):447-450.
315-322. 157. Runge JW, Martinez JC, Caravati EM, Williamson SG, Hartsell
140. Cerecedo I, Zamora J, Shreffler WG, et al. Mapping of the IgE SC. Histamine antagonists in the treatment of acute allergic
and IgG4 sequential epitopes of milk allergens with a pep- reactions. Ann Emerg Med. March 1992;21(3):237-242.
tide microarray-based immunoassay. J Allergy Clin Immunol. 158. Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines
September 2008;122(3):589-594. for the treatment of anaphylaxis: Cochrane systematic review.
141. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of Allergy. August 2007;62(8):830-837.
choice for anaphylaxis. A statement of the World Allergy 159. Gueugniaud PY, David JS, Chanzy E, et al. Vasopressin and
Organization. Allergy. August 2008;63(8):1061-1070. epinephrine vs. epinephrine alone in cardiopulmonary resusci-
142. Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline tation. N Engl J Med. July 3, 2008;359(1):21-30.
for the treatment of anaphylaxis: cochrane systematic review. 160. Choong K, Bohn D, Fraser DD, et al. Vasopressin in pediatric
Allergy. February 2009;64(2):204-212. vasodilatory shock: a multicenter randomized controlled trial.
143. Guidelines to minimize the risk from systemic reactions caused Am J Respir Crit Care Med. October 1, 2009;180(7):632-639.
by immunotherapy with allergenic extracts. AAAI Board of 161. De Backer D, Biston P, Devriendt J, et al. Comparison of dopa-
Directors. American Academy of Allergy and Immunology. J mine and norepinephrine in the treatment of shock. N Engl J
Allergy Clin Immunol. April 1994;93(4):811-812. Med. March 4, 2010;362(9):779-789.
144. Bousquet J, Lockey R, Malling HJ, et al. Allergen immu- 162. Kill C, Wranze E, Wulf H. Successful treatment of severe ana-
notherapy: therapeutic vaccines for allergic diseases. World phylactic shock with vasopressin. Two case reports. Int Arch
Health Organization. American academy of Allergy, Asthma Allergy Immunol. July 2004;134(3):260-261.
and Immunology. Ann Allergy Asthma Immunol. November 163. Williams SR, Denault AY, Pellerin M, Martineau R. Vasopressin
1998;81(5, pt 1):401-405. for treatment of shock following aprotinin administration. Can
145. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace J Anaesth. February 2004;51(2):169-172.
DV. American Academy of Allergy, Asthma & Immunology/ 164. Choo KJ, Simons E, Sheikh A. Glucocorticoids for the treatment
American College of Allergy, Asthma and Immunology Joint of anaphylaxis: Cochrane systematic review. Allergy. October
Task Force Report on omalizumab-associated anaphylaxis. J 2010;65(10):1205-1211.
Allergy Clin Immunol. December 2007;120(6):1373-1377. 165. Lieberman P. Biphasic anaphylactic reactions. Ann Allergy
146. Committee on Drugs: anaphylaxis. Pediatrics. January 1973; Asthma Immunol. September 2005;95(3):217-226; quiz 226, 258.
51(1):136-140. 166. Vander Zanden JA, Valuck RJ, Bunch CL, Perlman JI, Anderson
147. The use of epinephrine in the treatment of anaphylaxis. AAAI C, Wortman GI. Systemic adverse effects of ophthalmic beta-
Board of Directors. J Allergy Clin Immunol. October 1994; blockers. Ann Pharmacother. December 2001;35(12):1633-1637.
94(4):666-668. 167. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic
148. Winslow CM, Austen KF. Enzymatic regulation of mast drugs, and adrenergic receptor antagonists. In: Goodman LS,
cell activation and secretion by adenylate cyclase and cyclic Limbird LE, Milinoff PB, Ruddon RW, Gilman AG, eds.
AMP-dependent protein kinases. Fed Proc. January 1982; The Pharmacologic Basis of Therapeutics. 9th ed. New York:
41(1):22-29. McGraw-Hill; 1990:209.
149. Fisher MM. The management of anaphylaxis. Med J Aust. May 168. Hiatt WR, Wolfel EE, Stoll S, et al. Beta-2 adrenergic blockade
21, 1977;1(21):793. evaluated with epinephrine after placebo, atenolol, and nadolol.
Clin Pharmacol Ther. January 1985;37(1):2-6.
150. Fisher M. Blood volume replacement in acute anaphylactic
cardiovascular collapse related to anaesthesia. Br J Anaesth. 169. Motulsky HJ, Insel PA. Adrenergic receptors in man: direct
October 1977;49(10):1023-1026. identification, physiologic regulation, and clinical alterations.
N Engl J Med. July 1, 1982;307(1):18-29.
151. Beaupre PN, Roizen MF, Cahalan MK, Alpert RA, Cassorla L,
Schiller NB. Hemodynamic and two-dimensional transesopha- 170. Zaloga GP, DeLacey W, Holmboe E, Chernow B. Glucagon
geal echocardiographic analysis of an anaphylactic reaction in a reversal of hypotension in a case of anaphylactoid shock. Ann
human. Anesthesiology. May 1984;60(5):482-484. Intern Med. July 1986;105(1):65-66.
152. Philbin DM, Moss J, Akins CW, et al. The use of H1 and H2 his- 171. Pollack CV Jr. Utility of glucagon in the emergency department.
tamine antagonists with morphine anesthesia: a double-blind J Emerg Med. March-April 1993;11(2):195-205.
study. Anesthesiology. September 1981;55(3):292-296. 172. Sherman MS, Lazar EJ, Eichacker P. A bronchodilator action of
153. Lin RY, Curry A, Pesola GR, et al. Improved outcomes in glucagon. J Allergy Clin Immunol. May 1988;81(5, pt 1):908-911.
patients with acute allergic syndromes who are treated with 173. Thomas M, Crawford I. Best evidence topic report. Glucagon
combined H1 and H2 antagonists. Ann Emerg Med. November infusion in refractory anaphylactic shock in patients on beta-
2000;36(5):462-468. blockers. Emerg Med J. April 2005;22(4):272-273.

Section11-O-Ref.indd 5 12/10/2014 8:08:30 PM